Antifungal azoles for skin disorders

Bibliography

• WEITZMAN I, SUMMERBELL RC: The dermatophytes. Clin. Microbiol. Rev. (1995) 8:240-259.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO T: Fungal diseases in dermatology. In: Principle and Practice of Clinical Mycology. Kibber CC, Mackenzie DWR, Odds FC (Eds). John Willey & Sons Ltd, England (1996):103-129.
   Google Scholar
• FAERGEMANN J: Atopic dermatitis and fungi. Clin. Microbiol. Rev (2002) 15:545-563.
   PubMed Web of Science ®Google Scholar
• BORGERS M: Ultrastructural correlates of antimycotic treatment. In: Current Topics in Medical Mycology. McGinnis M (Ed.). Springer, Berlin, (1988) 2:1-39.
   Google Scholar
• SLOBODA RD, VAN BLARICOM G, CREASEY WA, ROSENBAUM JL, MALAWISTA SE: Griseofulvin: association with tubulin and inhibition of in vitro microtubule assembly. Biochem. Biophys. Res. Commun. (1982) 105:882-888.
   PubMed Web of Science ®Google Scholar
• HAZEN KC: Fungicidal activity of terbinafine and itraconazole in vitro. J. Am. Acad. Dermatol. (1998) 38:S37-S41.
   PubMed Web of Science ®Google Scholar
• RYDER NV, MIETH: Allylamine antifungal drugs. In: Current Topics in Medical Mycology. Borgers, Hay, Rinaldi (Eds). Springer, New York (1992) 4:158-188.
   Google Scholar
• HARTMAN PG, POLAK A: Preclinical data of amorolfine. In: Cutaneous Antifungal Agents. Rippon JW, Fromtling RA (Eds). Marcel Dekker, New York (1993):13-26.
   Google Scholar
• VANDEN BOSSCHE H: Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. In:Current Topics in Medical Mycology. McGinnis MR (Ed.) Springer, New York (1985) 1:313-359.
   Google Scholar
• KOBAYASHI D, KONDO K, UEHARA N et al.: Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect. Antimicrob. Agents Chemother. (2002) 45:3113-3117.
   Web of Science ®Google Scholar
• WOOLLEY DW: Some biological effects produced by benzimidazole and their reversal by purines. J. Biol. Chem. (1944) 152:225-232.
   Google Scholar
• DEGREEF H, VAN DE KERCKHOVE M, GEVERS D, VAN CUTSEM J, VANDEN BH, BORGERS M: Ketoconazole (R 41 400) in the treatment of dermatophyte infections: a clinical, mycological, and morphological study. Int. J. Dermatol. (1981) 20(10):662-667.
   PubMed Web of Science ®Google Scholar
• PALACIN C, TARRAGE C, ORTIZ JA: Sertaconazole pharmacology of a gynecological antifungal agent. Int. J. Gynaecol. Obstet. (2000) 71(1):837-846.
   Google Scholar
• CARRILLO-MUNOZ AJ, GAGLIETTA A, PALACIN C et al.: In vitro antifungal activity of sertaconazole compared with nine other drugs against 250 clinical isolates of dermatophytes and scopulariopsis brevicaulis. Chemotherapy (2004) 50:308-313.
   PubMed Web of Science ®Google Scholar
• MAERTENS JA: History of the development of azole derivatives. Clin. Microbiol. Infec. (2004) 10(1):1-10.
   PubMed Web of Science ®Google Scholar
• DE NOLLIN S, VAN BELLE H, GOOSSENS F, THONE F, BORGERS M: Cytochemical and biochemical studies of yeast after in vitro exposure to miconazole. Antimicrob. Agents Chemother. (1977) 11:500-513.
   PubMed Web of Science ®Google Scholar
• FRANCOIS IE, CAMMUE B, BORGERS M, AUSMA J, DISPERSYN GD, THEVISSEN K: Azoles: mode of antifungal action and resistance development. Effect of miconazole on endogenous reactive oxygen species production in Candida albicans. Anti-Infective Agents in Med. Chem. (2006) 5:3-13.
   Google Scholar
• DUMITRI R, HORNBY JM, NICKERSON KW: Defined anaerobic growth medium for studying Candida albicans basic biology and resistance to eight antifungal drugs. Antimicrob. Agents Chemother. (2004) 48(7):2350-2354.
   PubMed Web of Science ®Google Scholar
• SUD IJ, FEINGOLD DS: Action of antifungal imidazoles on Staphylococcus aureus. Antimicrob. Agents Chemother. (1982) 22:470-474.
   PubMed Web of Science ®Google Scholar
• ROSEN T, SCHELL BY, ORENGO I: Anti-inflammatory activity of antifungal preparations. Int. J. Dermatol. (1997) 36:788-794.
   PubMed Web of Science ®Google Scholar
• FAERGEMANN J: Management of seborrhoeic dermatitis and pityriasis versicolor. Am. J. Clin. Dermatol. (2000) 1:75-80.
   PubMedGoogle Scholar
• SANGLARD D, BILLE J: Current understanding of the modes of action of and resistance mechanisms to conventional and emerging antifungal agents for treatment of Candida infections. In: Candida and candidiasis. Calderone RA (Ed.). ASM Press, Washington, DC (2002) 349-383.
   Google Scholar
• NIIMI M, NIIMI K, TAKANO Y et al.: regulated overexpression of CDR1 in Candida albicans confers multidrug resistance. J. Antimicrob. Chemother. (2004) 54(6):999-1006.
   PubMed Web of Science ®Google Scholar
• SANGUINETTI M, POSTERARO B, FIORI B, RANNO S, TORELLI R, FADDA G: Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob. Agents Chemother. (2005) 49(2):668-679.
   PubMed Web of Science ®Google Scholar
• DE BRABANDER M, AERTS F, VAN CUTSEM J, VANDEN BH, BORGERS M: The activity of ketoconazole in mixed cultures of leukocytes and Candida albicans. Sabouraudia (1980) 18:197-210.
   PubMedGoogle Scholar
• CETINKAYA Z, KIRAZ N, KARACA S et al.: Antifungal susceptibilities of dermatophytic agents isolated from clinical specimens. Eur. J. Dermatol. (2005) 5:258-261.
   Google Scholar
• RICHARDSON K: The discovery of fluconazole. In: Cutaneous Antifungal Agents Rippon JW, Fromtling RA (Eds). Marcel Dekker, New York (1993) 171-185.
   Google Scholar
• NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS (NCCLS): Reference method for broth dilution antifungal susceptibility testing of conidium forming filamentous fungi. proposed standard, NCCLS document M38-P: Wayne PA (1997) 18(13).
   Google Scholar
• NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS (NCCLS): Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard (2nd Ed) NCCLS: Wayne PA (2002) 17(9).
   Google Scholar
• BOLOGNIA JL, JORRIZZO JL, RAFINI PR: In: Dermatology. Mosby (Ed.) Elsevier Limited, London. (2003) 20-24.
   Google Scholar
• DEGREEF H: Itraconazole in the treatment of tinea capitis. Cutis (1996) 58(1):90-93.
   PubMed Web of Science ®Google Scholar
• DEGREEF H, DE DONCKER P: In: Fighting fungal infections around the globe. (Ed.) Wells Publ. Medical Holdings, England. (2000) 85-95.
   Google Scholar
• GINTER-HANSELMEYER G, SMOLLE J, GUPTA A: Itraconazole in the treatment of tinea capitis caused by Microsporum canis: experience in a large cohort. Pediatr. Dermatol. (2005) 22(4):499-502.
   Google Scholar
• FLEECE D, GANGHAN JP, ARONOFF SC: Griseofulvin versus terbinafine in the treatment of tinea capitis. Pediatrics (2004) 144:1312-1315.
   Google Scholar
• SCHER RK: Onychmycosis: a significant medical disorder. J. Am. Acad. Dermatol. (1996) 35(3 Pt 2):S2-S5.
   PubMed Web of Science ®Google Scholar
• BOLOGNIA JL, JORIZZO JL, RAFINI PR: In: Dermatology. (Ed.) Mosby, Elsevier Limited, London. (2003) 1184
   Google Scholar
• GUPTA AK, RYDER JE: The use of oral antifungal agents to treat onychomycosis. Dermatolog. Clin. (2003) 21:469-479.
   PubMed Web of Science ®Google Scholar
• DOMPMARTIN D, DOMPMARTIN A, DELUOL AM, GROSSHOUS E, COULAUD AV: Onychomycoses and AIDS. Clinical and Laboratory findings in 62 patients. Int. J. Dermatol. (1990) 29:337-339.
   PubMed Web of Science ®Google Scholar
• FARRE B, GHANNORIM MA, RYDER NS: Biochemical characterization of terbinafine-resistant Trichophytes rubrum isolates. Med. Mycol. (2004) 42:525-529.
   PubMed Web of Science ®Google Scholar
• DANIER CR: Traditional management of onychomycosis. J. Am. Acad. Dermatol. (1996) 35:521-525.
   Google Scholar
• BARAN R, HAY RJ: Partial fungical avulsion of the nail in onychomycosis. Clin. Exp. Dermatol. (1985) 10:413-418.
   PubMed Web of Science ®Google Scholar
• NOLTING S: Non-traumatic removal of the nail and simultaneous treatment of onychomycosis. Wien. Med. Wochenschr. (1989) 139:354-355.
   PubMed Web of Science ®Google Scholar
• HAY RJ, MACKIE RM, CLAYTON YM: Tioconazole nail solution: an open study of its efficacy in onychomycos. Clin. Exp. Dermatol. (1985) 10:111-115.
   PubMed Web of Science ®Google Scholar
• HAY RJ, ROBERTS DT, DOHERTY VR, RICHARDSON MD, MIDGLEY G: The topical treatment of onychomycosis using a new combined urea/imidazole preparation. Clin. Exp. Dermatol. (1988) 13:164-167.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, TOMAS E: New antifungal agents. Dermatol. Clin. (2003) 21:565-576.
   PubMed Web of Science ®Google Scholar
• HARIA M, BRYSON HM: Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs (1995) 49:103-120.
   PubMed Web of Science ®Google Scholar
• DEGREEF H, DE DONCKER P: Current therapy of dermotophytosis: J. Am. Acad. Dermatol. (1993) 31:S25-S30.
   Google Scholar
• WILLEMSEN M, DE DONCKER P, WILLEMS J et al.: Post treatment itraconazole levels in the nail. New implications for treatment in onychomycosis. J. Am. Acad. Dermatol. (1992) 26:731-735.
   PubMed Web of Science ®Google Scholar
• CAUWENBERGH G, DEGREEF H, HEYKANTS J et al.: Pharmacokinetic profile of orally administered itraconazole in human skin. J. Am. Acad. Dermatol. (1988) 18(2 Pt. 1):263-268.
   PubMed Web of Science ®Google Scholar
• SIGURGEIRSON B, OLAFSSON JH, STEINSSON JB et al.: Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch. Dermatol. (2002) 138:353-357.
   PubMedGoogle Scholar
• BARAN R: Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost effective treatment for onychomycosis. Br. J. Dermatol. (2001) 145(60):15-19.
   PubMed Web of Science ®Google Scholar
• LECHA M: Amorolfine and itraconazole combinations for severe toenail onychomycosis: results of an open randomized trial in Spain. Br. J. Dermatol. (2001) 145(Suppl. 60):21-26.
   PubMed Web of Science ®Google Scholar
• AVNER S, NIR N, HENRI T: Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J. Dermatolog. Treat. (2005) 16:327-330.
   PubMed Web of Science ®Google Scholar
• BARAN R, KAOUKHOV A: Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J. Eur. Acad. Dermatol. (2005) 19:21-29.
   Web of Science ®Google Scholar
• HUI X, CHAN TC, BARBADILLIO S et al.: Enhanced econazole penetration into human nail by 2-n-monyl-1,3-dioxatane. J. Pharm. Sci. (2003) 92:142-148.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, LYNDE CW, KONNIKOV N: Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse for the treatment of toenail onychomycosis. J. Am. Acad. Dermatol. (2001) 44:485-491.
   PubMed Web of Science ®Google Scholar
• CARDOT JM, CHAUMONT C, DUBRAY C et al.: Comparison of the pharmacokinetics of miconazole after administration via a bioadhesive slow release tablet and an oral gel to healthy and female subjects. Br. J. Clin. Pharmacol. (2004) 58:345-348.
   PubMed Web of Science ®Google Scholar
• MOHAMMED FA, KHEDR H: Preparation and in vivo/in vitro evaluation of the buccal bio adhesive properties of slow-release tablets containing miconazole nitrate. Durg. Dev. Ind. Pharm. (2003) 29:321-327.
   PubMed Web of Science ®Google Scholar
• SPRAKER MK, GISOLDI EM, SIEGFRIED EC et al.: Topical miconazole nitrate ointment in the treatment of diaper dermatitis complicated by Candidiasis. Cutis (2006) 77:113-120.
   PubMed Web of Science ®Google Scholar
• PIÉRARD-FRANCHIMONT C, ARRESE JE, PIÉRARD GE: How to manage seborrheic dermatitis. Rev. Med. Liège (2003) 58:67-69.
   PubMedGoogle Scholar
• GUPTA AK, NICOL K, BATRA R: Role of antifungal agents in the treatment of seborrheic dermatitis. Am. J .Clin. Dermatol. (2004) 5(6):417-422.
   PubMed Web of Science ®Google Scholar
• FAERGEMANN J: Management of seborrheic dermatitis and pityriasis versicolor. Am. J. Clin. Dermatol. (2000) 1(2):75-80.
   PubMedGoogle Scholar
• PIÉRARD-FRANCHIMONT C, VROOME V, CAUWENBERGH G, PIÉRARD GE: Corneofungimetry bioassay on Malassezia spp. under ketoconazole and desonide influences. Skin Pharmacol. Physiol. (2005) 18:98-102.
   PubMed Web of Science ®Google Scholar
• BEGER B, HIGHTON A, BARRANCO C, LEGENDRE R: A double-blind, randomized, vehicle-controlled, parallelgroup, multicenter study to assess the efficacy and safety of a topical gel product containing ketoconazole SP 2% in the treatment of seborrheic dermatitis. J. Am. Acad. Dermatol. (2005) 52:122 (Abstract).
   PubMed Web of Science ®Google Scholar
• BEGER B, HIGHTON A, LEGENDRE R: The irritation potential of topical formulations containing ketoconazole 2% and desonide 0.05% alone and in combination. J. Am. Acad. Dermatol. (2005) 52:61(abstract).
   Web of Science ®Google Scholar
• UCHIDA K, NISHIYAMA Y, TANAKA T, YAMAGUCHI H: In vitro activity of novel imidazole antifungal agent NND-502 against Malassezia species. Int. J. Antimicrob. Agents (2003) 21:234-238.
   PubMed Web of Science ®Google Scholar
• KUZAHARA N, KODAMA H, YOSHIDA M, MIYAZAKI T, YAMAGUCHI H: In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent. Antimicrob. Agents Chemother. (1998) 42:967-970.
   PubMed Web of Science ®Google Scholar
• UCHIDA K, NISHIYAMA Y, YAMAGUCHI H: In vitro activity of luliconazole (NND-502), a novel imidazole antifungal agent. J. Infect. Chemother. (2004) 10:216-219.
   PubMedGoogle Scholar
• NIWANO Y, KUZAHARA N, GOTO Y et al.: Efficacy of NND-502, a novel imidazole antimycotic agent, in experimental models of Candida albicans and Aspergillus fumigatus infections. Int. J. Antimicrob. Agents (1999) 12:221-228.
   PubMed Web of Science ®Google Scholar
• NIWANO Y, KOGA H, KODAMA H, KANAI K, MIYAZAKI T, YAMAGUCHI H: Inhibition of sterol 14α-demethylation of Candida albicans with NND-502, a novel optically active imidazole antimycotic agent. Med. Mycology (1999) 37:351-355.
   PubMed Web of Science ®Google Scholar
• ROSSELLO A, BERTINI S, LAPUCCI A et al.: Synthesis, antifungal activity, and molecular modeling studies of new inverted oxime ethers of oxiconazole. J. Med. Chem. (2002) 45:4903-4912.
   PubMed Web of Science ®Google Scholar
• SILVESTRY R, ARTICO M, LA REGINA G et al.: Imidazole analogues of fluoxetine, a novel class of anti-Candida agents. J. Med. Chem. (2004) 47:3924-2926.
   PubMed Web of Science ®Google Scholar
• SAHA AK, LIU L, MARICHAL P, ODDS F: Novel antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl sulphonamides towards optimization of in vitro activity. Bioorg. Med. Chem. Lett. (2000) 10:2735-2739.
   PubMed Web of Science ®Google Scholar
• FOSTEL JM, LARTEY PA: Emerging novel antifungal agents. Drug Discov. Today (2000) 5:25-32.
   PubMed Web of Science ®Google Scholar
• OHWADA J, TSUKAZAKI M, HAYASE T et al.: Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole. Bioorg. Med. Chem. Lett. (2003) 13:191-196.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI K, HORII I: Comparative toxicological assessment of a water-soluble azole administered both orally and by intravenous continuous infusion in cynomolgus monkeys. J. Tox. Sci. (2002) 27:107-122.
   PubMedGoogle Scholar
• GUPTA AK, RYDER JE: The use of oral antifungal agents to treat onychomycosis. Dermatolog. Clin. (2003) 21:469-479.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, THOMAS E: New antifungal agents. Dermatol. Clin. (2003) 21:565-576.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-TORRES B, CARRILLO AJ, MARTIN E et al.: In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob. Agents Chemother. (2001) 45:2524-2528.
   PubMed Web of Science ®Google Scholar
• GHANNOUM MA, CHATURVEDI V, ESPINEL-INGROFF A et al.: Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes. J. Clin. Microb. (2004) 42:2977-2979.
   PubMed Web of Science ®Google Scholar
• FAVRE B, HOFBAUWER B, HILDERING KS, RYDER NS: Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes by using a microdilution assay. J. Clin. Microb. (2003) 41:4817-4819.
   PubMed Web of Science ®Google Scholar
• BARCHIESI F, ARZENI D, CAMILETTI V et al.: In vitro activity of posaconazole against clinical isolates of dermatophytes. J. Clin. Microb. (2001) 39:4208-4209.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, KOHLI Y, BATRA R: In vitro activity of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. Med. Mycol. (2005) 43:179-185.
   PubMed Web of Science ®Google Scholar
• VAN LOO D: Voriconazole: an evaluation of activity and use. J. Infect. Dis. Pharmacother. (2003) 6:15-37.
   Google Scholar
• KAMAI Y, HARASAKI T, FUKUOKA T et al.: In vitro and in vivo activities of CS-758 (R-120758), a new trizole antifungal agent. Antimicrob. Agents Chemother. (2002) 46:367-370.
   PubMed Web of Science ®Google Scholar
• KONOSU T, FUKUOKA T: CS-758, a new triazole antifungal agent: synthesis, structure–activity relationships and antifungal activity. Ann. Rep. Sankyo Res. Lab. (2001) 53:81-92.
   Google Scholar
• KAMAI Y: CS-758, a new triazole agent: In vivo antifungal activity against experimental Candidiasis, Aspergillosis, and Cryptococcosis. Ann. Rep. Sankyo Res. Lab. (2004) 56:1-10.
   Google Scholar
• MEERPOEL L, BACKX LJJ, VAN DER VEKEN LJ et al.: Synthesis and in vitro and in vivo structure–activity relationship of novel antifungal triazoles for dermatology. J. Med. Chem. (2005) 48:2184-2193.
   PubMed Web of Science ®Google Scholar
• ODDS F, AUSMA J, VAN GERVEN F et al.: In vitro and in vivo activities of the novel azole antifungal agent R126638. Antimicrob. Agents Chemother. (2004) 48:388-391.
   PubMed Web of Science ®Google Scholar
• FAERGEMANN J, AUSMA J, BORGERS M: The in vitro activity of R126638 and ketoconazole against Malassezia species. Acta. Derm. Venereol. (2006) In press.
   Google Scholar
• FAERGEMANN J, AUSMA J, WOUTERS L, BORGERS M: An open label trial to evaluate the effect of oral treatment with R126638 in pityriasis versicolor. JEADV (2005) 19(2):1-91(Abstract).
   Web of Science ®Google Scholar
• PIERARD-FRANCHIMONT C, AUSMA J, WOUTERS L et al.: The activity of R126638, a new triazole antifungal, as assessed by corneofungimetry. Skin Pharmacol. Physiol. (2006) 19:50-56.
   PubMed Web of Science ®Google Scholar
• AUSMA J, WOUTERS L, VANDEPLASSCHE L, BORGERS M, DECROIX J: Effect of a new azole R126638 in tinea pedis: pilot trial of a 3 or 5 days treatment. JEADV (2005) 19(2):1-87(Abstract).
   Web of Science ®Google Scholar